🟢 Opus Genetics is trading 6.3% up today after corrected OPGx-BEST1 data supported Phase 3

Opus Genetics is trading at $6.45, up +6.29% after correcting an immaterial visual-acuity calculation error in OPGx-BEST1 Cohort 1 data.

• The revised presentation still showed tolerability and retinal improvements.
• 75% of evaluable participants met the potential FDA-aligned microperimetry endpoint, supporting advancement toward Phase 3; pivotal-trial dosing could begin in 2027.
• Broader markets are also higher after in-line inflation data.